ArticleClinical drug investigation2026
Retrospective Real-World Comparison of Adherence, Persistence, Health-Care Utilization, and Costs Among Biologics for Moderate-to-Severe Psoriasis in China.
Article in Clinical drug investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesBiologics have significantly enhanced treatment for psoriasis but data regarding their treatment patterns and economic burden are limited. The aim of this study was to evaluate adherence, persistence, switching, health-care resource utilization (HCRU) and costs among secukinumab, adalimumab, ustekinumab, and ixekizumab in China.
methodsThis retrospective observational study identified adult patients with psoriasis who initiated biologics between 1 January 2020 and 30 June 2022, from the Regional Medical Big Data of Tianjin, China (comprising hospital information system data from 43 tertiary and 39 secondary hospitals). Treatment adherence was assessed using the Proportion of Days Covered (PDC) and PDC ≥ 80% was defined as adherence. Persistence was defined as continuous use of the index biologic without a gap > 180 days between consecutive prescriptions until end of follow-up. Psoriasis-related and all-cause health-care utilization and direct medical costs (Chinese Yuan, ¥) were assessed over a 1-year follow-up period.
resultsA total of 1646 patients (mean age 43.7 ± 14.0 years; 67.0% male) were included of whom 1306, 182, 98, and 60 initiated treatments with secukinumab, adalimumab, ustekinumab, and ixekizumab, respectively. Patient medication adherence decreased over time. At 12 months, ustekinumab and ixekizumab had similar persistence rates (65.9% and 64.7%, P = 0.588), while secukinumab and adalimumab had lower rates (32.3% and 17.9%, respectively, P < 0.001). Only 3.0% of the overall patients switched to second-line therapy. Patients treated with secukinumab and adalimumab more frequently used outpatient services (95.6% and 99.5% visited annually, P < 0.001), while a higher proportion of ustekinumab and ixekizumab patients were hospitalized (81.6% and 83.3%, respectively, P < 0.001). The annual costs were highest for patients initiated with ustekinumab (¥22,727 ± 11,028), followed by secukinumab (¥20,037 ± 13,369), driven by the drug costs of biologics.
conclusionsThis study suggests that ustekinumab and ixekizumab are associated with better adherence and persistence compared with secukinumab and adalimumab. Ustekinumab and ixekizumab are primarily used during hospitalization, possibly owing to their high unit price or low injection frequency. Cost-effective treatment options that enhance treatment adherence and persistence are required.
Identifiers
42593668What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.